Angiogenesis in Cancers
Tumor progression is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors. Inflammatory infiltration contributes to tumor progression and metastatic process, and there are many rep...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_98959 | ||
| 005 | 20230405 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-6917-8 | ||
| 020 | |a 9783036569161 | ||
| 020 | |a 9783036569178 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-6917-8 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Ribatti, Domenico |4 edt | |
| 700 | 1 | |a Ribatti, Domenico |4 oth | |
| 245 | 1 | 0 | |a Angiogenesis in Cancers |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (274 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Tumor progression is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors. Inflammatory infiltration contributes to tumor progression and metastatic process, and there are many reports of associations between tumor inflammatory infiltration, progression and prognosis. New therapeutic approaches have been developed with the aim to control tumor progression through the targeting of different components of the tumor microenvironment. This reprint will be useful for anyone who wants to learn about cancer: professors and students at universities, scientists at research institutes, biotechnology, and pharmaceutical labs, and lawyers trying to understand the patent literature. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a RBP4 | ||
| 653 | |a metastasis | ||
| 653 | |a breast cancer | ||
| 653 | |a angiogenesis | ||
| 653 | |a endothelial dysfunction | ||
| 653 | |a STAT3 | ||
| 653 | |a VEGF | ||
| 653 | |a endothelin-1 | ||
| 653 | |a resveratrol | ||
| 653 | |a gemcitabine | ||
| 653 | |a endoglin | ||
| 653 | |a ERKs | ||
| 653 | |a microvessel growth | ||
| 653 | |a lung cancer | ||
| 653 | |a cancer | ||
| 653 | |a anticancer | ||
| 653 | |a DLBCL | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a cell adhesion mediated drug resistance | ||
| 653 | |a tumor progression | ||
| 653 | |a VEGFR | ||
| 653 | |a anti-angiogenesis | ||
| 653 | |a anti-angiogenic agents | ||
| 653 | |a immunosuppression | ||
| 653 | |a immunotherapy | ||
| 653 | |a immune-checkpoint inhibitors | ||
| 653 | |a combination therapy | ||
| 653 | |a tumor angiogenesis | ||
| 653 | |a endothelium | ||
| 653 | |a microenvironment | ||
| 653 | |a multiple myeloma | ||
| 653 | |a adhesion molecules | ||
| 653 | |a immune-checkpoint inhibitor | ||
| 653 | |a tumor-derived exosomes | ||
| 653 | |a small extracellular vesicles | ||
| 653 | |a feline mammary carcinoma | ||
| 653 | |a VEGF-A | ||
| 653 | |a VEGFR-1 | ||
| 653 | |a VEGFR-2 | ||
| 653 | |a non-invasive biomarkers | ||
| 653 | |a selectins | ||
| 653 | |a E-selectin | ||
| 653 | |a uproleselan | ||
| 653 | |a adrenal fetal cortex | ||
| 653 | |a adrenocortical tumors | ||
| 653 | |a adrenocortical carcinoma | ||
| 653 | |a anti-angiogenic drugs | ||
| 653 | |a bFGF | ||
| 653 | |a anti-angiogenic therapy | ||
| 653 | |a resistance | ||
| 653 | |a vascular permeability | ||
| 653 | |a drug delivery system | ||
| 653 | |a microbeam radiation therapy (MRT) | ||
| 653 | |a Chicken Chorioallantoic Membrane (CAM) | ||
| 653 | |a U-87 Glioblastoma | ||
| 653 | |a ginsenoside Rg3 | ||
| 653 | |a response surface methodology | ||
| 653 | |a optimisation | ||
| 653 | |a epimer | ||
| 653 | |a long pentraxin 3 | ||
| 653 | |a FGF/FGFR system | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7012 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98959 |7 0 |z DOAB: description of the publication |